Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart Failure
- 27 October 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 90 (8), 905-911
- https://doi.org/10.1097/tp.0b013e3181f10edb
Abstract
Background. Patients with light chain (AL) amyloidosis who present with severe heart failure due to cardiac involvement rarely survive more than 6 months. Survival after cardiac transplantation is markedly reduced due to the progression of amyloidosis. Autologous stem-cell transplantation (ASCT) has become a common therapy for AL amyloidosis, but there is an exceedingly high treatment-related mortality in patients with heart failure. Methods. We developed a treatment strategy of cardiac transplant followed by ASCT. Twenty-six patients were evaluated, and of 18 eligible patients, nine patients underwent cardiac transplantation. Eight of these patients subsequently received an ASCT. Results. Six of seven evaluable patients achieved a complete hematologic remission, and one achieved a partial remission. At a median follow-up of 56 months from cardiac transplant, five of seven patients are alive without recurrent amyloidosis. Their survival is comparable with 17,389 patients who received heart transplants for nonamyloid heart disease: 64% in nonamyloid vs. 60% in amyloid patients at 7 years (P=0.83). Seven of eight transplanted patients have had no evidence of amyloid in their cardiac allograft. Conclusions. This demonstrates that cardiac transplantation followed by ASCT is feasible in selected patients with AL amyloidosis and heart failure, and that such a strategy may lead to improved overall survival.Keywords
This publication has 24 references indexed in Scilit:
- Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid CardiomyopathyThe Journal of Heart and Lung Transplantation, 2008
- Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantationBlood, 2007
- Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasoneHaematologica, 2007
- Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationBlood, 2006
- Sequential heart and autologous stem cell transplantation for systemic AL amyloidosisBlood, 2006
- Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosisBone Marrow Transplantation, 2005
- Outcome of Heart Transplantation in Patients With Amyloid CardiomyopathyThe Journal of Heart and Lung Transplantation, 2005
- Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateBone Marrow Transplantation, 2004
- Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control studyBlood, 2004
- Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapyBritish Journal of Haematology, 2003